ArticleLiver cancer2025

Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis.

Stephen Lam Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.